CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). VIII. THE EFFECT OF BAL ON THE EXCRETION OF ARSENIC IN ARSENICAL INTOXICATION 1
Open Access
- 1 July 1946
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 25 (4) , 534-540
- https://doi.org/10.1172/jci101735
Abstract
Urinary As has been detd. before and after BAL therapy in 16 patients with arsenical intoxication and in 2 patients receiving arsenical treatment without reaction. Of 24 courses of BAL admn., 16 were followed by a definite increase in As excretion, 4 by a possible increase, and 4 by no increase. On no occasion was there a decreased excretion of As during BAL treatment. The increase in urinary As after BAL appears to be more consistent in patients with arsenical dermatitis than in hepatitis, suggesting a correlation with the greater efficacy of BAL in the treatment of dermatitis. The increases of urinary organic S and reducing substances coincide with the increased urinary As after BAL admn., lending support to the idea that the excretion of BAL or a closely related substance is associated with the increased As excretion.Keywords
This publication has 6 references indexed in Scilit:
- CLINICAL USES OF 2,3—DIMERCAPTOPROPANOL (BAL). I. THE SYSTEMIC TREATMENT OF EXPERIMENTAL ARSENIC POISONING (MAPHARSEN, LEWISITE, PHENYL ARSENOXIDE) WITH BAL 1Journal of Clinical Investigation, 1946
- CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). VII. THE TREATMENT OF ARSENICAL DERMATITIS WITH PREPARATIONS OF BALJournal of Clinical Investigation, 1946
- BAL (British Anti-Lewisite)Science, 1945
- ENZYME SYSTEMS CONTAINING ACTIVE SULFHYDRYL GROUPS. THE ROLE OF GLUTATHIONEScience, 1943
- Public Health Weekly Reports for JANUARY 29, 1932.1932
- Chemical constitution and toxicityBiochemical Journal, 1928